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Abstract. Dipyridamole, a traditional anti‑platelet drug, has 
been reported to inhibit the proliferation of cancer cells. 
The present study aimed to investigate the possibility of 
dipyridamole as an adjuvant of chemotherapy by enhancing 
the cytotoxicity of an anti‑cancer drug. The cytotoxicity of 
colorectal cancer cells (HCT‑8), CD133+/CD44+ stem‑like 
subpopulation of HCT‑8 cells and lymphoma cells (U937) to 
dipyridamole and/or doxorubicin was evaluated using MTT 
proliferation and colony forming assays. The expression levels 
of phosphorylated cAMP‑regulatory element‑binding protein 
(pCREB) and poly(ADP‑ribose) polymerase‑1 (PARP‑1) in 
cells were analyzed via western blotting and immunofluores‑
cence. The present study reported controversial data regarding 
the anti‑cancer effect of dipyridamole. Dipyridamole 
increased, rather than inhibited, the proliferation of HCT‑8 and 
U937 cells in a dose‑dependent manner. Furthermore, it was 
found that dipyridamole significantly increased the expression 
levels of pCREB and PARP‑1. However, the combined usage 
of dipyridamole significantly enhanced the cytotoxicity of 
doxorubicin to HCT‑8 cells at particular doses. Based on the 
current findings, dipyridamole likely induces the phosphoryla‑
tion of CREB to promote the proliferation of cancer cells, but 
may enhance the cytotoxicity of anti‑cancer drugs at particular 
doses.
Introduction
Dipyridamole, a traditional anti‑platelet agent, is an inhibitor of 
phosphodiesterase enzyme 3 (PDE3) and PDE5, which results in 
the accumulation of cyclic adenosine monophosphate (cAMP) 
and cyclic guanosine monophosphate (cGMP) (1), consequently 
increasing protein kinase A (PKA) and PKG, respectively (2). 
Previous studies have reported that dipyridamole enhances 
the cytotoxicity of anti‑tumor drugs, such as 5‑flurouracil (3), 
cisplatin (4) and methotrexate (5,6), as well as preventing tumor 
progression (7) and decreasing the proliferative activity of 
cancer cells (2,8). Although dipyridamole has been reported to 
inhibit the re‑uptake of adenosine and downregulate cyclin D1 
and c‑Myc levels (7), the precise role and the relevant mecha‑
nism of dipyridamole in regulating the proliferation of cancer 
cells is yet to be elucidated. Moreover, there is no consensus on 
the anti‑cancer effect of dipyridamole.
Complex signaling pathways are known to mediate the 
proliferation, survival and therapeutic resistance of cancer 
cells (9). Of which, cAMP‑regulatory element‑binding 
protein (CREB) has been demonstrated to serve a critical 
role in both hematologic and non‑hematologic malignan‑
cies (10,11) via the phosphorylation of various kinases, such 
as Akt and PKA (12,13). Moreover, the cAMP/PKA axis 
has been demonstrated to regulate poly(ADP‑ribose) poly‑
merase‑1 (PARP‑1) (14), which is known to serve an important 
role not only in DNA repair (15), but also the development and 
progression of malignant tumors (16,17). As dipyridamole may 
induce the accumulation of cAMP and cGMP to support the 
survival and proliferation of cells, the precise role of dipyri‑
damole on the proliferation of cancer cells requires further 
investigation.
Doxorubicin is a widely prescribed chemotherapeutic drug, 
but its use in high doses is limited due to serious side effects, 
such as myelotoxicity and cardiotoxicity (18). Considering the 
favorable safety profile of dipyridamole, it will be beneficial to 
use dipyridamole as adjuvant drug for enhancing the sensitivity 
of cancer cells to doxorubicin. Therefore, the present study 
aimed to investigate the anti‑cancer effect of dipyridamole in 
combination with doxorubicin.
Using human colorectal cancer cells (HCT‑8), 
CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells and 
human monocyte histiocytic lymphoma cells (U937), it was 
identified that dipyridamole increased, rather than inhibited, 
the proliferation of HCT‑8 and U937 cells in a dose‑dependent 
manner. However, the cytotoxicity of doxorubicin was 
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enhanced by the combined usage of dipyridamole at particular 
doses.
Materials and methods
Cell culture. Human colorectal cancer cells (HCT‑8), 
CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells and 
human monocyte histiocytic lymphoma cells (U937) were 
used for the experiments. Cells were maintained in RPMI‑1640 
medium (Fujifilm Wako, Inc.) supplemented with 10% FBS 
(Corning, Inc.) and 1% penicillin/streptomycin (Fujifilm 
Wako, Inc.), at 37˚C in a humidified atmosphere with 5% CO2 
and 95% air.
Cytotoxicity assay. Based on previous publications (2,7,8), we 
used 0, 10 and 20 µM dipyridamole in this study. For doxoru‑
bicin, we used the same dose of 0, 1.0 and 3.0 µM for HCT‑8 
cells as our previous study (19). However, the cytotoxicity 
of doxorubicin largely vary among cancer cell lines (20). As 
cytotoxicity of doxorubicin to U937 cells was highly indicated 
even at dose of 0.5 µM in our preliminary experiment, we used 
0, 0.1 and 0.2 µM doxorubicin for U937 cells in this study. 
Cytotoxicity assay was performed using the Cell Proliferation 
Kit I (MTT) according to the manufacturer's protocol (Roche 
Diagnostics). Briefly, cells were seeded in 96‑well culture 
plates (5x103 cells/well) and cultured overnight. Cells were then 
treated with various concentrations of doxorubicin (Fujifilm 
Wako, Inc.) and dipyridamole (Sigma‑Aldrich; Merck KGaA). 
At 24 h after treatment, MTT was added and incubated for 
another 4 h. The formation of formazan from MTT was 
stopped by adding solubilization solution, and the absorbance 
of formazan was measured at 570 nm using a microplate reader 
(iMark™ Microplate Reader; Bio‑Rad Laboratories, Inc.). 
The optical density (OD) value of cells with vehicle treatment 
was used as a normalization control (100%). The combina‑
tion effect was analyzed with coefficient of drug interaction 
[CDI = AB/(A x B)], where AB is the OD value ratio of the 
combination group and vehicle groups, A is the OD value ratio 
of the drug A and vehicle groups, and B is the OD value ratio 
of the drug B and vehicle groups. CDI value <1 indicates a 
synergistic effect, CDI value =1 indicates an additive effect 
and CDI value >1 indicates an antagonistic effect. Optical 
density (OD); coefficient of drug interaction (CDI).
Colony forming assay (CFA). A CFA was performed to 
confirm the MTT assay data of dipyridamole in regulating 
the proliferation of parent and CD133+/CD44+ stem‑like 
subpopulation of HCT‑8 cells. After treatment with 20 µM 
dipyridamole for 24 h, the cells were collected, re‑cultured 
in 6‑well culture plate (200 cells/well) and incubated for 10 
days. Colonies were fixed with 4% formalin (Fujifilm Wako, 
Inc.) for 20 min and stained with 0.5% crystal violet solution 
for 1 h. Colonies were counted using ImageJ 2.1.0 software 
(National Institutes of Health).
Western blotting. Western blotting was performed as previously 
described (21). Briefly, cells were lysed in Laemmli's buffer. 
Total proteins were separated using SDS‑PAGE and were then 
transferred to PVDF membranes (Bio‑Rad Laboratories, Inc.). 
After blocking, the membranes were incubated with primary 
antibodies against rabbit phosphorylated (p)CREB (Ser133; 
1:1,000, cat. no. ab32096; Abcam), rabbit PARP‑1 (1:1,000 cat. 
no. 9542; Cell Signaling Technology, Inc.) and mouse α‑tubulin 
(1:1,000, cat. no. 3873; Cell Signaling Technology, Inc.) which 
was followed by incubation with appropriate horseradish 
peroxidase‑conjugated secondary antibodies against rabbit 
(1:2,000, cat. no. p0448; Dako Agilent Technologies) and 
mouse (1:2,000, cat. no. p0260; Dako Agilent Technologies). 
The expression was visualized using an ECL detection kit 
(cat. no. RPN2106; Cytiva). Images were acquired using 
ImageQuant LAS 4000 Mini biomolecular imager (Cytiva). 
Semi‑quantification on the relative expression of proteins was 
performed using ImageJ 2.1.0 software (National Institutes of 
Health).
Immunofluorescence staining. Immunofluorescence staining 
was performed to detect the expression of pCREB. Briefly, 
cells were fixed with 4% formalin (Fujifilm Wako, Inc.) for 
10 min. After blocking, cells were incubated with primary 
antibodies against pCREB (1:100) at room temperature for 1 h, 
followed by incubation with an Alexa Fluorescent 546‑conju‑
gated secondary antibody against rabbit Ig (1:500 cat. 
no. A11035; Invitrogen; Thermo Fisher Scientific, Inc.) at 
room temperature for 1 h in the dark. The cell nuclei were 
labeled with DAPI.
Statistical analysis. Data are presented as the mean ± SEM for 
three independent experiments. The data were analyzed using 
one‑way ANOVA, followed by Tukey's multiple comparison 
post‑test. P<0.05 was considered to indicate a statistically 
significant difference. All analyses were performed using 
GraphPad Prism 8.0 software or Excel Microsoft 365.
Results
Dipyridamole increases the proliferation of cancer cells. 
A MTT assay is used to evaluate the proliferation of cancer 
cells. The addition of dipyridamole (0‑20 µM) increased 
the proliferation of U937 cells, parent HCT‑8 cells and the 
CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells in a 
dose‑dependent manner (Fig. 1A).
To further assess the data of the MTT assay, a colony 
forming assay was conducted for parent and CD133+/CD44+ 
stem‑like subpopulation of HCT‑8 cells. Dipyridamole (20 µM) 
increased the number of colonies for parent HCT‑8 cells (from 
748±70 to 866±172; P=0.33) and CD133+/CD44+ stem‑like 
subpopulation of HCT‑8 cells (from 761±122 to 1106±176; 
P=0.04) (Fig. 1B). Based on these findings, dipyridamole may 
promote, but not inhibit the proliferation of cancer cells.
Dipyridamole enhances the expression levels of pCREB 
and PARP‑1. Western blotting was performed to investigate 
the potential mechanism on the proliferation of cancer cells 
induced by dipyridamole. It was identified that the expression 
of pCREB in all cancer cells was increased at 30 or 60 min 
after 20 µM dipyridamole treatment (Fig. 2A). The enhanced 
expression of pCREB was also confirmed via immuno‑
fluorescence staining (Fig. 2B). Furthermore, the expression of 
PARP‑1 in all cancer cells was enhanced at 30 or 60 min after 
20 µM dipyridamole treatment (Fig. 3).
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Cytotoxicity of doxorubicin is enhanced by dipyridamole at 
particular doses. To evaluate whether dipyridamole enhances 
the cytotoxicity of doxorubicin to cancer cells, various doses of 
dipyridamole were added to cancer cells in combination with 
doxorubicin treatment. The correct doses for both drugs were 
chosen according to the reported literature and preliminary 
experiments (19,20), and the IC50 values of doxorubicin were 
calculated as 5.95 µM for HCT‑8 cells, 10.63 µM for the subpop‑
ulation of CD133+/CD44+ HCT‑8 cells and 0.29 µM for U937 
cells (Fig. S1). As indicated by the quantitative data of the MTT 
assay (Fig. 4; Table SI), dipyridamole significantly enhanced the 
sensitivity of cancer cells to doxorubicin, but only at a particular 
dose (10 µM dipyridamole with 3 µM doxorubicin for HCT‑8 
cells). However, dipyridamole at any of the other doses failed to 
demonstrate a significant enhancement of doxorubicin cytotox‑
icity to these cancer cells (Fig. 4; Tables SII and SIII).
Discussion
Dipyridamole, one of the most commonly used anti‑platelet 
agents, is also often prescribed to some patients with cancer. 
Previous studies have reported that dipyridamole sensitizes 
cancer cells to chemotherapeutic agents (2‑7). Although 
dipyridamole exerts an anti‑proliferative effect on breast and 
prostate cancer cells (2,7), the anti‑cancer benefit of dipyri‑
damole to patients with cancer is yet to be fully elucidated.
The present study aimed to investigate the precise role 
on the anti‑cancer benefit of dipyridamole. In contrast to 
previous studies (2‑7), the present results suggested that 
dipyridamole increased the proliferation of parent HCT‑8 
cells, CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells 
and U937 cells in a dose‑dependent manner. Although the 
current study neither evaluated cAMP or cGMP levels, nor the 
activation of cAMP/PKA or cGMP/PKG signaling pathways, 
the increased cell proliferation induced by dipyridamole 
could be explained as follows: PDE3 and PDE5 are exten‑
sively expressed in healthy tissue cells (22), and upregulated 
in multiple cancer cells, including HCT‑8 and U937 (13,23). 
As an inhibitor of PDE3 and PDE5, dipyridamole usually 
induces the accumulation of cAMP and cGMP in cells (1). 
cAMP and cGMP are generally known to activate PKA and 
PKG, respectively, which induces the phosphorylation of 
CREB (13,24) and pCREB regulates the expression of several 
genes involved in the metabolism, proliferation, differentia‑
tion and survival of cells (12). Thus, we speculate that the 
increased cellular levels of cAMP and cGMP contribute 
to the small beneficial effect of dipyridamole on the cell 
survival/proliferation (up to around 20% by MTT assay). 
Moreover, the present results indicated that dipyridamole 
increased the expression of pCREB in U937 lymphoma cells, 
parent HCT‑8 colorectal cancer cells and the CD133+/CD44+ 
stem‑like subpopulation from HCT‑8 cells. Although we 
have not yet investigated, it is possible that other PDE3 and 
PDE5 inhibitors may also beneficial of cell proliferation. The 
current findings suggested that dipyridamole enhanced the 
expression of PARP‑1, which known to support the survival 
Figure 1. Proliferation of HCT‑8 cells, CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells and U937 cells. (A) MTT assay was used to assess the viability 
of cancer cells treated with various doses of dipyridamole. (B) Colony forming assay was used to assess the proliferation of parent and CD133+/CD44+ 
stem‑like subpopulation of HCT‑8 cells.
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and proliferation of cancer cells. Thus, dipyridamole may 
promote, rather than inhibit, the survival and proliferation of 
cells, but further details of the relevant mechanisms require 
additional investigations.
Doxorubicin is commonly used for in vitro experiments 
and clinics (21,25‑30). However, doxorubicin is rarely 
prescribed to patients with colorectal cancer as the expres‑
sion of P‑glycoprotein in colorectal cancer contributes to 
doxorubicin resistance (23,26). As dipyridamole has been 
reported to inhibit P‑glycoprotein (28), synergistic effects 
of dipyridamole and doxorubicin are expected for patients 
with colon cancer. The present study investigated whether 
dipyridamole could enhance the cytotoxicity of doxorubicin 
to these cancer cells. Interestingly, the cytotoxicity of doxo‑
rubicin was significantly enhanced by dipyridamole, only to 
HCT‑8 cells in particular dose. A previous study also reported 
that dipyridamole alone or in combination with methotrexate 
failed to increase the cytotoxicity in leukemia cells (29). In 
fact, the small compound of dipyridamole not only inhibits 
PDE3 and PDE5, but also regulates multiple cell signaling 
pathways (2,7). Therefore, the anti‑cancer effect of dipyri‑
damole used alone or with doxorubicin may largely depend on 
the cell types and other conditions (30). Further basic experi‑
ments using additional cancer cell lines, as well as clinical 
Figure 2. Expression of pCREB in HCT‑8 cells, CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells and U937 cells. (A) Western blot analysis of the 
expression of pCREB in cells treated with 20 µM dipyridamole. (B) Immunofluorescence staining of the expression of pCREB in cells 60 min after treatment 
with 20 µM dipyridamole (magnification, x60). pCREB, phosphorylated cAMP‑regulatory element‑binding protein.
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data, are required to confirm the potential anti‑cancer effect 
of dipyridamole.
In conclusion, to the best of our knowledge, the present 
preliminary data from in vitro experiments indicated for the 
first time that dipyridamole enhanced doxorubicin sensi‑
tivity at particular doses. As dipyridamole was also found to 
improve the survival and proliferation of cancer cells, it may 
be prescribed cautiously for patients with cancer.
Figure 3. Expression of PARP‑1 in HCT‑8 cells, CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells and U937 cells treated with 20 µM dipyridamole. 
Representative images and semi‑quantitative data of western blot analysis. PARP‑1, poly(ADP‑ribose) polymerase‑1.
Figure 4. MTT assay was used to analyze the proliferation of (A) HCT‑8 cells, (B) CD133+/CD44+ stem‑like subpopulation of HCT‑8 cells and (C) U937 cells. 
Cancer cells were treated with dipyridamole and doxorubicin at different doses.




The present study was supported by the Egyptian ministry of 
Higher Education (grant no. CAM‑751‑FM‑06‑01).
Availability of data and materials
All data generated or analyzed during this study are included 
in this published article.
Authors' contributions
LA performed the experiments, acquired, analyzed and inter‑
preted the data, and drafted the manuscript. NEM designed 
the current study and gave final approval for the manuscript 
to be published. TK and SG performed the experiments. TSL 
conceived the current study, performed the experiments and 
wrote and reviewed the final manuscript. TSL also gave final 
approval for the manuscript to be published and supervised 
the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
 1. Gresele P, Momi S and Falcinelli E: Anti‑platelet therapy: 
Phosphodiesterase inhibitors. Br J Clin Pharmacol 72: 634‑646, 2011. 
 2. Thomé MP, Pereira LC, Onzi GR, Rohden F, Ilha M, Guma FT, 
Wink MR and Lenz G: Dipyridamole impairs autophagic flux 
and exerts antiproliferative activity on prostate cancer cells. Exp 
Cell Res 382: 111456, 2019.
 3. Kohnoe S, Maehara Y, Takahashi I, Emi Y, Baba H and 
Sugimachi K: Treatment of advanced gastric cancer with 5‑fluo‑
rouracil and cisplatin in combination with dipyridamole. Int J 
Oncol 13: 1203‑1206, 1998. 
 4. Rodrigues M, Barbosa F Jr and Perussi JR: Dipyridamole 
increases the cytotoxicity of cisplatin in human larynx cancer 
cells in vitro. Braz J Med Biol Res 37: 591‑599, 2004. 
 5. Kennedy DG, Van den Berg HW, Clarke R and Murphy RF: 
Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 
human breast cancer cell line by dipyridamole. The role of metho‑
trexate polyglutamates. Biochem Pharmacol 35: 3053‑3056, 1986. 
 6. Van Mouwerik TJ, Pangallo CA, Willson JK and Fischer PH: 
Augmentation of methotrexate cytotoxicity in human colon 
cancer cells achieved through inhibition of thymidine salvage by 
dipyridamole. Biochem Pharmacol 36: 809‑814, 1987.
 7. Spano D, Marshall JC, Marino N, De Martino D, Romano A, 
Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita G, et al: 
Dipyridamole prevents triple‑negative breast‑cancer progression. 
Clin Exp Metastasis 30: 47‑68, 2013. 
 8. Ge SM, Zhan DL, Zhang SH, Song LQ and Han WW: Reverse 
screening approach to identify potential anti‑cancer targets of 
dipyridamole. Am J Transl Res 8: 5187‑5198, 2016.
 9. Sakamoto KM and Frank DA: CREB in the pathophysiology of 
cancer: Implications for targeting transcription factors for cancer 
therapy. Clin Cancer Res 15: 2583‑2587, 2009.
10. Crans HN and Sakamoto KM: Transcription factors and translocations 
in lymphoid and myeloid leukemia. Leukemia 15: 313‑331, 2001.
11. Seo H, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, 
Wistuba II and Koo JS: CREB Overexpression: A Feature 
Associated with Negative Prognosis in Never‑Smokers with 
NSCLC. Cancer Res 68: 6065‑6073, 2008.
12. Shaywitz AJ and Greenberg ME: CREB: A stimulus‑induced 
transcription factor activated by a diverse array of extracellular 
signals. Annu Rev Biochem 68: 821‑861, 1999. 
13. Fajardo AM, Piazza GA and Tinsley HN: The role of cyclic 
nucleotide signaling pathways in cancer: Targets for prevention 
and treatment. Cancers (Basel) 6: 436‑458, 2014. 
14. Brunyanszki A, Olah G, Coletta C, Szczesny B and Szabo C: 
Regulation of mitochondrial poly(ADP‑Ribose) polymerase acti‑
vation by the β‑adrenoceptor/cAMP/protein kinase A axis during 
oxidative stress. Mol Pharmacol 86: 450‑462, 2014. 
15. De Vos M, Schreiber V and Dantzer F: The diverse roles and 
clinical relevance of PARPs in DNA damage repair: Current 
state of the art. Biochem Pharmacol 84: 137‑146, 2012. 
16. Addioui A, Belounis A, Cournoyer S, Nyalendo C, Brito RM, 
Beaunoyer M, Teira P and Sartelet H: Preclinical study of a PARP 
inhibitor in neuroblastoma. J Clin Oncol 30 (Suppl 15): 9570, 2012. 
17. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou‑Maroun LM, 
Liu M, Lonigro R, Prensner JR, Tomlins SA, et al: PARP‑1 
inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer 
Res 72: 1608‑1613, 2012.
18. Zaremba T, Thomas H, Cole M, Plummer ER and Curtin NJ: 
Doxorubicin‑induced suppression of poly(ADP‑ribose) poly‑
merase‑1 (PARP‑1) activity and expression and its implication 
for PARP inhibitors in clinical trials. Cancer Chemother 
Pharmacol 66: 807‑812, 2010. 
19. Yan C, Luo L, Guo CY, Goto S, Urata Y, Shao JH and Li TS: 
Doxorubicin‑induced mitophagy contributes to drug resistance 
in cancer stem cells from HCT8 human colorectal cancer cells. 
Cancer Lett 388: 34‑42, 2017. 
20. Kibria G, Hatakeyama H, Akiyama K, Hida K and Harashima H: 
Comparative study of the sensitivities of cancer cells to doxo‑
rubicin, and relationships between the effect of the drug‑efflux 
pump P‑gp. Biol Pharm Bull 37: 1926‑1935, 2014. 
21. Yan C, Luo L, Goto S, Urata Y, Guo CY, Doi H, Kitazato K and 
Li TS: Enhanced autophagy in colorectal cancer stem cells does 
not contribute to radio‑resistance. Oncotarget 7: 45112‑45121, 2016. 
22. Omori K and Kotera J: Overview of PDEs and their regulation. 
Circ Res 100: 309‑327, 2007. 
23. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, 
Degenhardt J, Mayba O, Gnad F, Liu J, et al: A comprehensive 
transcriptional portrait of human cancer cell lines. Nat 
Biotechnol 33: 306‑312, 2015. 
24. Wong JC, Bathina M and Fiscus RR: Cyclic GMP/protein 
kinase G type‑Iα (PKG‑Iα) signaling pathway promotes CREB 
phosphorylation and maintains higher c‑IAP1, livin, survivin, 
and Mcl‑1 expression and the inhibition of PKG‑Iα kinase 
activity synergizes with cisplatin in non‑small cell lung cancer 
cells. J Cell Biochem 113: 3587‑3598, 2012. 
25. Ragazzi E, Berti E, Chiodo R, Dancona S and Berti T: 
Dipyridamole as a modulator of multidrug‑resistance in 
tumor‑cells in‑vitro. Int J Oncol 6: 659‑662, 1995. 
26. Weinländer G, Kornek G, Raderer M, Hejna M, Tetzner C and 
Scheithauer W: Treatment of advanced colorectal cancer with doxo‑
rubicin combined with two potential multidrug‑resistance‑reversing 
agents: High‑dose oral tamoxifen and dexverapamil. J Cancer Res 
Clin Oncol 123: 452‑455, 1997. 
27. Krishan A, Sridhar KS, Mou C, Stein WD, Lyubimov E, Hu YP 
and Fernandez H: Synergistic effect of prochlorperazine and 
dipyridamole on the cellular retention and cytotoxicity of doxo‑
rubicin. Clin Cancer Res 6: 1508‑1517, 2,000.
28. Wessler JD, Grip LT, Mendell J and Giugliano RP: The 
P‑glycoprotein transport system and cardiovascular drugs. J Am 
Coll Cardiol 61: 2495‑2502, 2013. 
29. Nelson JA and Drake S: Potentiation of methotrexate toxicity by 
dipyridamole. Cancer Res 44: 2493‑2496, 1984.
30. Solomon EI, Augustine AJ and Yoon J: O2 reduction to H2O by 
the multicopper oxidases. Dalton Trans 30: 3921‑3932, 2008.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International (CC BY-NC-ND 4.0) License.
